Adult Pneumococcal Disease: Know Your Options-
Pneumococcal bacteria are a leading cause of infectious disease in the United States. Adults are particularly vulnerable to invasive pneumococcal disease that is associated with significant morbidity and mortality. These infections also place a heavy financial burden on the healthcare system due to frequent and prolonged hospitalization. The clinical and economic costs attributed to these infections are expected to increase due to the aging of the US population and increased longevity of patients with immunosuppressive conditions. This is despite the availability of effective preventive measures, such as vaccination, that are critical in maintaining quality of life in the adult patient population, especially in the era of multidrug resistance.
Explain the healthcare burden of pneumococcal disease among adults
Evaluate the benefits and limitations of pneumococcal vaccines for use in specific patient populations
Identify adults at risk for pneumococcal disease and patients who will benefit from vaccination
Recognize and reduce patient-related and process-related barriers to pneumococcal vaccination
Vaccinate patients in accordance with current clinical practice recommendations
Pneumococcal bacteria are a leading cause of infectious disease in the United States. Adults are particularly vulnerable to invasive pneumococcal disease that is associated with significant morbidity and mortality. These infections also place a heavy financial burden on the healthcare system due to frequent and prolonged hospitalization. The clinical and economic costs attributed to these infections are expected to increase due to the aging of the US population and increased longevity of patients with immunosuppressive conditions. This is despite the availability of effective preventive measures, such as vaccination, that are critical in maintaining quality of life in the adult patient population, especially in the era of multidrug resistance.
Explain the healthcare burden of pneumococcal disease among adults
Evaluate the benefits and limitations of pneumococcal vaccines for use in specific patient populations
Identify adults at risk for pneumococcal disease and patients who will benefit from vaccination
Recognize and reduce patient-related and process-related barriers to pneumococcal vaccination
Vaccinate patients in accordance with current clinical practice recommendations
2.0 Free AMA Pra Cat 1 CME for Physicians
Expires 2/7/13